Trial Profile
A Phase 2A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Varoglutamstat (PQ912) in Patients With Early Alzheimer's Disease With a Stage-Gate to Phase 2B (VIVA-MIND)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Apr 2024
Price :
$35
*
At a glance
- Drugs Varoglutamstat (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
- Acronyms VIVA-MIND
- Sponsors Vivoryon Therapeutics
- 24 Apr 2024 According to a Vivoryon Therapeutics media release, Initial data from the study is anticipated by the end of 2024.
- 24 Apr 2024 According to a Vivoryon Therapeutics media release, Based on the VIVIAD analysis, and an assessment of funding needs, we have taken the decision, jointly with principal investigator, to discontinue the VIVA-MIND study in early AD in the second half of 2024.
- 23 Oct 2023 According to a Vivoryon Therapeutics media release, the company is now recruiting participants into the second cohort with 21 sites open across the U.S.